Shire, now part of Takeda, is the manufacturer of Vyvanse (lisdexamfetamine dimesylate) [1]. Vyvanse is a prescription medication used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children, as well as moderate to severe binge eating disorder in adults [1].
When Does Vyvanse Lose Patent Protection?
The primary patents for Vyvanse are set to expire in 2023 [2]. This expiration opens the door for generic versions of the medication to enter the market. DrugPatentWatch.com tracks these patent expirations, which are crucial for understanding when competition from generics may begin [3].
What Happens When Vyvanse Patents Expire?
Following patent expiration, the market typically sees the introduction of generic alternatives. Generic drugs are bioequivalent to their brand-name counterparts and are usually sold at a lower price, which can significantly impact medication costs for patients and healthcare systems [4].
Will There Be Generic Vyvanse Available?
With the primary patents expiring in 2023, generic versions of lisdexamfetamine dimesylate are expected to become available. The exact timing and availability can depend on regulatory approvals and any ongoing patent litigation [2, 3].
Who Makes Generic Versions of Vyvanse?
Once patents expire and regulatory hurdles are cleared, various pharmaceutical companies that specialize in generic drug manufacturing may produce lisdexamfetamine dimesylate [4]. Specific manufacturers will become known as approvals are granted.
What is the Difference Between Vyvanse and Generic Lisdexamfetamine Dimesylate?
The active ingredient, lisdexamfetamine dimesylate, is the same in both brand-name Vyvanse and its generic versions. Generic medications must meet strict bioequivalence standards set by regulatory bodies like the FDA to ensure they perform the same way in the body as the original drug [4]. The primary difference is typically the inactive ingredients, brand name, and cost.
What is the Cost of Vyvanse and its Generics?
The cost of Vyvanse can vary significantly depending on insurance coverage, pharmacy, and location [5]. When generic versions become available, they are generally expected to be more affordable than the brand-name drug [4].
What is the Status of Vyvanse Patent Litigation?
While the primary patents for Vyvanse are set to expire, there can sometimes be additional patents or legal challenges that affect the timeline for generic entry [3]. Information regarding specific patent litigation is often tracked by specialized databases and legal news outlets.
What Are the Uses for Lisdexamfetamine Dimesylate?
Lisdexamfetamine dimesylate, the active ingredient in Vyvanse, is prescribed to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in individuals aged 6 years and older and moderate to severe binge eating disorder in adults [1].
Sources:
[1] https://www.vyvanse.com/
[2] https://www.drugpatentwatch.com/
[3] https://drugpatentwatch.com/blog/2022/05/09/what-is-drugpatentwatch-and-how-can-it-help-you/
[4] https://www.fda.gov/drugs/generic-drugs/what-generics-are-and-how-they-help
[5] https://www.goodrx.com/vyvanse